Cidara Retained Earnings Total Equity from 2010 to 2025

CDTX Stock  USD 22.39  0.81  3.75%   
Cidara Therapeutics Retained Earnings Total Equity yearly trend continues to be fairly stable with very little volatility. Retained Earnings Total Equity is likely to outpace its year average in 2025. Retained Earnings Total Equity is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. View All Fundamentals
 
Retained Earnings Total Equity  
First Reported
2015-03-31
Previous Quarter
-403.8 M
Current Value
-416.1 M
Quarterly Volatility
124 M
 
Yuan Drop
 
Covid
Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14.7 M or Other Operating Expenses of 186.2 M, as well as many indicators such as Price To Sales Ratio of 141, Dividend Yield of 0.0 or PTB Ratio of 1.1. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Latest Cidara Therapeutics' Retained Earnings Total Equity Growth Pattern

Below is the plot of the Retained Earnings Total Equity of Cidara Therapeutics over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. Cidara Therapeutics' Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Retained Earnings Total Equity10 Years Trend
Slightly volatile
   Retained Earnings Total Equity   
       Timeline  

Cidara Retained Earnings Total Equity Regression Statistics

Arithmetic Mean(204,022,333)
Geometric Mean139,374,325
Coefficient Of Variation(75.61)
Mean Deviation139,518,083
Median(149,390,000)
Standard Deviation154,261,338
Sample Variance23796.6T
Range361.5M
R-Value(0.93)
Mean Square Error3466.7T
R-Squared0.86
Slope(30,118,128)
Total Sum of Squares356948.4T

Cidara Retained Earnings Total Equity History

2025-348 M
2024-366.3 M
2021-407 M
2020-334.7 M
2019-259.8 M
2018-218.7 M
2017-149.4 M

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Retained Earnings Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings Total Equity-366.3 M-348 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.